A share price of Neurocrine Biosciences, Inc. [NBIX] is currently trading at $153.15, up 8.18%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NBIX shares have gain 4.83% over the last week, with a monthly amount glided 11.39%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Neurocrine Biosciences, Inc. [NASDAQ: NBIX] stock has seen the most recent analyst activity on April 24, 2024, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $170 from $140. On December 12, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $136 on the stock. Mizuho reiterated its recommendation of a Neutral and raised its price target to $113 on August 21, 2023. SVB Securities upgraded its rating to Outperform for this stock on July 24, 2023, and upped its price target to $125. In a note dated July 06, 2023, BMO Capital Markets upgraded an Market Perform rating on this stock and boosted its target price from $91 to $96.
Neurocrine Biosciences, Inc. experienced fluctuations in its stock price throughout the past year between $99.98 and $150.39. Currently, Wall Street analysts expect the stock to reach $141.74 within the next 12 months. Neurocrine Biosciences, Inc. [NASDAQ: NBIX] shares were valued at $153.15 at the most recent close of the market. An investor can expect a potential drop of -7.45% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
Trailing Twelve Months sales for Neurocrine Biosciences, Inc. [NASDAQ:NBIX] were 1.98B which represents 22.57% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.21%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.15 and Total Capital is 0.19. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 148.45 points at the first support level, and at 143.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 157.91, and for the 2nd resistance point, it is at 162.68.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Neurocrine Biosciences, Inc. [NASDAQ:NBIX] is 2.52. Also, the Quick Ratio is 2.47, while the Cash Ratio stands at 0.35. Considering the valuation of this stock, the price to sales ratio is 7.78, the price to book ratio is 6.46 and price to earnings (TTM) ratio is 42.10.
Transactions by insiders
Recent insider trading involved Lippoldt Darin, Chief Legal Officer, that happened on Jul 16 ’24 when 7004.0 shares were sold. Chief Regulatory Officer, Delaet Ingrid completed a deal on Jul 16 ’24 to sell 2857.0 shares. Meanwhile, Director LYONS GARY A sold 930.0 shares on Jul 16 ’24.
